

Title

Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India

Pragya Sharma¹, Suruchi Mishra¹, Saurav Basu¹, Neha Tanwar¹, Rajesh Kumar¹

¹ Department of Community Medicine, Maulana Azad Medical College, New Delhi

Abstract

Introduction

The study objective was to determine the breakthrough infection rate of Covid-19 (SARS-CoV-2) infection in those vaccinated with either BBV152 or AZD1222 (ChAdOx1-S) vaccine among healthcare workers (HCWs).

Methods

A cross-sectional analysis was conducted at a medical college and hospital complex in Delhi, India through telephonic interviews among HCWs who had received at least one dose of a Covid-19 vaccine during January to March 2021. Breakthrough infections were operationally defined as occurrence of Covid-19 infection ≥ 14 days after administration of two doses of either Covid-19 vaccine.

Results

We enrolled 326 HCWs with mean (SD) age of 29.1 (85.9) years including 212 (65%) males. Two hundred eighty (90.9%) HCWs were fully vaccinated while 46 (14.1%) were partially vaccinated. There were 168 (51.5%) BBV152 and 158 (48.5%) AZD1222 (ChAdOx1-S) recipients.

A total of 36 (11%, 95% C.I. 8.1, 14.9) breakthrough infections were reported in the HCWs. The median (IQR) time until incidence of Covid-19 infection since receiving second dose of either Covid-19 vaccine was 46 (28.2, 54.7) days. Furthermore, Covid-19 infections occurred in 65 (19.9%, 95% C.I. 15.9, 24.6) HCWs vaccinated with at least one dose of vaccine but prior to receiving their second dose or < 14 days post second dose. Most breakthrough infection cases (94.4%) were mild and did not require supplemental oxygen therapy. HCWs with past history of natural Covid-19 infection with recovery were 4.5 times less likely to experience a Covid-19 infection after partial vaccination.

Conclusion

Nearly one in nine HCWs experienced a Covid-19 breakthrough infection in the present study.

Keywords

Breakthrough infection; Covid-19; SARS-CoV-2; Covid-19 vaccination; India

Introduction

Vaccines are considered the mainstay in halting and ending the Covid-19 pandemic which has caused over 172 million cases and 3.7 million deaths worldwide till date [1]. India launched the world's largest Covid-19 mass vaccination campaign from January' 2021 in a phased manner beginning with healthcare, sanitation and essential frontline workers, followed by the geriatric population, people with comorbidities, those aged > 45 years and finally the entire adult population [2].

The vaccines approved and deployed in India by the regulatory authority included AZD1222 - ChAdOx1-S (Covishield), manufactured in India by Serum Institute of India through license from Astrazeneca-Oxford [3] and BBV152 (Covaxin), indigenous vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) [4]. The AZD122 (ChAdOx1-S/nCoV-19) recombinant vaccine against Covid-19 is a replication-deficient adenoviral vector vaccine that expresses the SARS-CoV-2 spike protein gene [3]. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine adjuvanted with Algel-IMDG to induce T-helper-1 cell (Th1) responses [4]. The efficacy of AZD1222 (ChAdOx1-S) after administration of two doses of the vaccines irrespective of interval between the doses has been reported as 63.1%, with possibly higher efficacy on longer intervals [3]. The interim phase-3 clinical trial data reported BBV152 to have efficacy of 78% against infection with SARS-CoV-2 [5]. However, the real-world effectiveness of vaccines may differ from the efficacy reported in clinical trials due to a multitude of factors including the dynamics of disease exposure, diminished antibody response in sub-groups like the elderly and the immunocompromised, and the emergence of newer mutant strains with greater infectivity and virulence [6, 7].

A small proportion of individuals will contract Covid-19 despite complete vaccination as no vaccine accords 100% protection against the disease, and occasionally newer virus variants evolve mechanisms for bypassing the vaccine induced antibody response. Breakthrough infections with reference to Covid-19 refers to the incidence of SARS-CoV-2 infections in individuals who have already been partially or completely vaccinated with any authorized Covid-19 vaccine [8].

According to the ICMR between 0.02 and 0.04% infections have occurred after partial or complete vaccination with either BBV152 or AZD1222 (ChAdOx1-S) [9]. However, healthcare workers (HCWs) represent a very high-risk group for contracting COVID-19 due

to sustained occupational exposure to the virus [10, 11], and the breakthrough infection rate assessed in this cohort would provide crucial evidence in understanding the effectiveness of vaccination in preventing symptomatic disease and disease transmission.

The study objective was therefore to determine the breakthrough infection rate of Covid-19 (SARS-CoV-2) infection in those vaccinated with either BBV152 or AZD1222 (ChAdOx1-S) vaccine among healthcare workers.

Methods

Study design and setting: We conducted a cross-sectional study among healthcare workers of the Maulana Azad Medical College, New Delhi most of whom provide services at the largest dedicated tertiary care Covid-19 hospital in Delhi. As per the government of India policy, two doses of either BBV152 (Covaxin) or AZD1222 (Covishield) vaccine at-least 4 weeks apart were available for administration to all HCWs since January 2021 with no mixing of doses allowed.

The primary outcome of the study was the proportion of breakthrough infection in HCWs which was defined as any Covid-19 infection occurring ≥ 14 days after receiving both the doses of either of the vaccine(s). The secondary outcome was the proportion of Covid-19 infections occurring post vaccination with at-least a single dose of vaccine but prior to receiving either the second dose or before 14 days after vaccination with the second dose. The independent variables included age, sex, time since vaccination, vaccine type, adherence to non-pharmaceutical measures post-vaccination and previous history of natural Covid-19 infection and recovery prior to vaccination.

The sample size was calculated considering the prevalence of breakthrough infection among HCWs in India as 13.3% as reported in a study from a chronic care facility in Delhi [12], at 95% confidence level, 4% precision, and 10% non-response. The minimum sample size was estimated as 270.

The data was collected during a period of 7 days from May 31 to June 6 through telephonic interviews conducted by multiple trained investigators using the following sources in a consecutive order: (i). Registration records of all the healthcare workers vaccinated at the Covaxin administration site within the college campus during February-March 2021 (ii). Records of the medical interns affiliated to the MAMC who were vaccinated between January-March' 2021.

Statistical analysis

Data was entered in Epidata 3.1 (single entered) and analysed with IBM SPSS Version 25 (Armonk, NY). Results were expressed in frequency and proportions for categorical variables, and mean and standard deviation for continuous variables. The significance of difference between proportions was assessed using the chi-square test. A p-value < 0.05 was considered statistically significant.

Ethics

The study was approved by the Institutional Ethics Committee (F.1/IEC/MAMC/(84/02/2021/No338). Verbal consent was obtained from the HCWs who responded to the telephonic interviews prior to the initiation of the survey.

Results

We enrolled a total of 326 healthcare workers including 259 medical doctors and interns (79.4%), 52 (15.9%) frontline health workers, 12 (4.6%) lab technicians and 3 (0.9%) nurses. The mean (SD) age of the participants was 29.1 (85.9) years including 212 (65%) males and 114 (35%) females. Two hundred eighty (90.9%) HCWs were fully vaccinated with two doses while 46 (14.1%) had received only one dose of a Covid-19 vaccine at the time of interview. There were 168 (51.5%) BBV152 recipients and 158 (48.5%) AZD1222 (ChAdOx1-S) recipients. Fifty (15.3%) HCWs reported a past history of natural Covid-19 infection and recovery prior to receiving the first dose of Covid-19 vaccine with 48 (94.1%) being mild cases and 3 (5.9%) being moderate cases needing supplemental oxygen therapy.

Covid-19 infections occurred in 65 (19.9%, 95% C.I 15.9, 24.6) HCWs vaccinated with at-least one dose of vaccine but prior to receiving either the second dose or before 14 days after vaccination with the second-dose. These infections were diagnosed with RT-PCR, Ag test, and on clinical suspicion in 50 (76.9%), 3 (4.6%), and 12 (18.5%) cases, respectively. The severity of Covid-19 infections were mild requiring only home isolation in 59 (90.8%) cases while 6 (9.2%) were moderate cases needing supplemental oxygen therapy. Within the households of HCWs suffering Covid-19 infection post-vaccination with at-least one dose of either Covid-19 vaccine, all members were diagnosed with Covid-19 during the same period in 13 (20%) cases while at-least one member was infected concurrently in 29 (44.6%) cases.

Furthermore, there were 36 (11%, 95% C.I. 8.1, 14.9) breakthrough infections of which 31 (86.1%), 3 (8.3%) and 2 (5.5%) cases were diagnosed with RT-PCR, Ag test and on the basis

of clinical symptoms, respectively. The median (IQR) time until incidence of Covid-19 infection since administration of the second dose of either Covid-19 vaccine was 46 (28.2, 54.7) days.

Among the HCWs experiencing a breakthrough infection, 34 (94.4%) were mild cases managed through only home isolation while there were 2 (5.6%) moderate cases requiring supplemental oxygen therapy prior to recovery. Within the households of HCWs reporting the incidence of a Covid-19 breakthrough infection, concurrent infection in all members was observed in 5 (13.9%) cases while at-least one member was infected in 15 (41.7%) cases.

Table 1 summarizes the Covid-19 infection rates in HCWs after administration of at-least a single dose of a Covid-19 vaccine. The proportion of Covid-19 infections post-vaccination in the Covaxin vaccinated group was higher than in the Covishield vaccinated group but this difference was not statistically significant ($p=0.332$). HCWs with a history of Covid-19 infection prior to vaccination were 4.5 times less likely to contract a Covid-19 infection or reinfection post Covid-19 vaccination.

The proportion of breakthrough infections did not show statistically significant variation when compared across subgroups including type of vaccine, age, sex, adherence to non-pharmaceutical measures after vaccination, and history of a natural Covid-19 infection prior to vaccination (Table 2).

Discussion

In this study, nearly, one in five HCWs reported the incidence of Covid-19 infection after receiving at-least one dose of a Covid-19 vaccine but before complete vaccination and 14 days post administration of the second vaccine dose. Furthermore, one in nine HCWs experienced a breakthrough infection after being administered both scheduled doses of either Covid-19 vaccine. These findings suggest that in real world settings a significant proportion of vaccinated individuals with high risk of exposure remain vulnerable to Covid-19 infection albeit with reduced disease severity in most cases.

Vaccine seroconversion through robust anti-spike antibody response is likely to be induced after a single dose of AZD1222 (ChAdOx1-S) compared to BBV152 wherein two doses are usually required to stimulate adequate antibody levels [7]. This study also observed the rates of Covid-19 infection after administration of at-least a single dose of vaccine were higher in the BBV152 group compared to the AZD1222 group, although statistical significance was not attained.

Evidence from a previous study suggests that a single dose of either BBV152 or AZD1222 induced higher concentration of neutralizing IgG antibody in those having a history of natural infection and recovery from COVID-19 [13]. Similarly, in this study, a history of a natural infection and recovery from Covid-19 was observed to be protective against a subsequent Covid-19 infection or reinfection in those HCWs who had been administered at-least a single dose of Covid-19 vaccine.

The rates of breakthrough infection observed in the present study (11%) were slightly lower than that observed during surveillance in a chronic care facility in Delhi, India (13.2%) where HCWs received either AZD1222 (ChAdOx1-S) or BBV152 [12]. However, another study in a large cohort of HCWs from a north Indian city vaccinated with AZD1222 (ChAdOx1-S) reported the incidence of Covid-19 breakthrough infections to be only 1.6% (48 out of 3,000) while 2.6% tested positive after receiving at-least one dose of the vaccine [14]. In contrast, Hacısuleyman et al. report the incidence of breakthrough infection as just 0.5% in a cohort of 417 health care workers who had previously received two doses the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine [15].

The period of observation in this study coincided with a massive wave of the Covid-19 epidemic in Delhi during April and May 2021 which witnessed 0.737 million cases including 11,075 deaths [16]. Furthermore, the emergent evidence from genomic analysis also reveals that the Covid-19 variants of concern, B.1.617.2 (Delta) and B.1.1.7 (Alpha) having ~50% higher transmissibility were primarily responsible for the surge in cases during the same period. These variants also constituted the predominant lineages found in the breakthrough infections cases due to a probable immune escape mechanism that could occasionally bypass the vaccine induced immunity [17]. Moreover, diminished neutralizing antibody activity and limited protectiveness against the delta variant of the SARS-CoV-2 has been observed in most of the currently available Covid-19 vaccines globally especially prior to complete vaccination with both vaccine doses [18, 19].

The strengths of the study are that it was conducted in real-world settings with the period of observation inclusive of the peak of the Covid-19 pandemic in Delhi, India when health systems were overwhelmed resulting in large scale viral exposure of HCWs providing either outpatient or inpatient treatment services. However, there are certain study limitations. First, since infection status of the HCWs was based on self-report in the absence of a mandatory testing policy, mostly symptomatic breakthrough infections diagnosed with RT-PCR or the

Ag test were likely to be captured while asymptomatic infections also capable of viral transmission were potentially omitted. Second, although, we observed high rates of transmission in the household members of the HCWs, the vaccination status in the infected household members was not recorded. Third, comorbidity status was not ascertained in the participants although the likelihood of underlying morbidities in the HCWs was less considering their low median age. Consequently, future studies should assess the extent of vaccine induced antibody response and protection after vaccination with Covid-19 vaccines in patients with diabetes, heart disease, chronic kidney disease, and older people at risk of reduced protection in addition to pre-existing concerns causally linked with the occurrence of severe disease. A final limitation is that the sample size was not adequately powered to detect statistically significant differences between subgroups.

In conclusion, breakthrough infections represent a major public health challenge in ending the Covid-19 pandemic. Robust surveillance through large-scale epidemiological studies to identify the predictors of breakthrough infection among individuals at risk, and rapid genomic analysis for early recognition of emerging variants of concern that have greater capability of causing breakthrough infections warrant continued prioritization.

Sources of support: Nil

Conflicts of interest: None

Table 1. Distribution of Covid-19 infections post first dose of vaccination in HCWs (N=326)

Characteristic	Total (N=326)	Total infections (n=65)	Unadjusted odds 95% C.I	p-value
Vaccination status				
Complete	280 (85.9)	53 (18.9)	0.66 (0.32, 1.4)	0.263
Partial	46 (14.1)	12 (26.1)	1	
Vaccine type				
BBV152	168 (51.5)	37 (22)	0.76 (0.44, 1.3)	0.332
AZD1222	158 (48.5)	28 (17.7)	1	
Age (Years)				
<35	255 (78.2)	52 (20.4)	0.87 (0.44, 1.7)	0.698
≥35	71 (21.8)	13 (18.3)	1	
Sex				
Male	212 (66.4)	46 (21.7)	0.72 (0.4, 1.3)	0.279
Female	114 (33.6)	19 (16.7)	1	
HCW Type				
Doctor	259 (79.4)	55 (21.2)	0.65 (0.31, 1.3)	0.252
Other	67 (20.6)	10 (14.9)	1	
History of Covid-19 infection*				
Present	50 (15.3)	3 (6)	1	0.014
Absent	276 (86.7)	62 (22.5)	4.5 (1.3, 15.1)	
Masking adherence ⁺				
Always	226 (69.3)	50 (22.1)	0.9 (0.51, 1.6)	0.714
Mostly/other	100 (30.7)	15 (15.0)	1	
Social distancing adherence ⁺				
Always	207 (63.5)	40 (19.3)	1	0.140
Mostly/other	119 (36.5)	25 (21)	1.6 (0.85, 3.0)	

*Prior to administration of the first dose of Covid-19 vaccine

+ Post vaccination with at-least one dose of vaccine

Table 2. Distribution of factors associated with Covid-19 breakthrough infections in HCWs (N=326)

Characteristic	Total (N=326)	Breakthrough infection (n=36)	Unadjusted odds 95% C.I	p-value
Vaccine type				
BBV152	168 (51.5)	23 (13.7)	1.8 (0.86, 3.6)	0.119
AZD1222	158 (48.5)	13 (8.2)	1	
Age (in Years)				
<35	255 (78.2)	30 (11.8)	1.4 (0.58, 3.6)	0.423
≥35	71 (21.8)	6 (8.5)	1	
Sex				
Male	212 (66.4)	26 (12.3)	1.4 (0.67, 3.1)	0.340
Female	114 (33.6)	10 (8.8)	1	
HCW Type				
Doctor	259 (79.4)	31 (12)	1.7 (0.63, 4.5)	0.299
Other	67 (20.6)	5 (7.5)	1	
History of Covid-19 infection*				
Present	50 (15.3)	3 (6)	1	0.226
Absent	276 (86.7)	33 (12)	2.1 (0.63, 7.2)	
Masking adherence ⁺				
Always	226 (69.3)	25 (11.1)	0.99 (0.47, 2.1)	0.987
Mostly/other	100 (30.7)	11 (11)	1	
Social distancing adherence ⁺				
Always	207 (63.5)	20 (9.7)	1	0.296
Mostly/other	119 (36.5)	16 (13.4)	1.4 (0.72, 2.9)	

*Prior to vaccination; + Post vaccination with at-least one dose of vaccine

REFERENCES

1. John Hopkins Coronavirus Resource Tracker. Available from <https://coronavirus.jhu.edu/map.html>. Last accessed on 6th June, 2021.
2. PM Launches pan India rollout of COVID-19 vaccination drive. <https://pib.gov.in/Pressreleaseshare.aspx?PRID=1689021>. Ministry of Health and Family Welfare. Last accessed on 6th June, 2021.
3. World Health Organization. COVID-19 Vaccines. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines>. Last accessed on: 6th June, 2021.
4. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *Lancet Infect Dis.* 2021;S1473-3099(20)30942-7. doi:10.1016/S1473-3099(20)30942-7
5. Hindustan Times. Covaxin efficacy 78% in Phase 3 analysis. May 29' 2021. <https://www.hindustantimes.com/india-news/covaxin-efficacy-78-in-phase-3-analysis-101622227104005.html> Last accessed 6th June 2021
6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020 Dec 31;383(27):2603-2615.
7. Singh AK, Phatak SR, Singh NK, Gupta A, Sharma A, Bhattacharjee K, et al. Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre. medRxiv [Internet]. 2021 Jan 1;2021.04.07.21255078. Last accessed 6th June 2021
8. CDC. Breakthrough case investigations and reporting. Available from: <https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html>. Last accessed on: 6th June 2021.
9. 2-4 per 10,000 people infected after getting vaccinated, Covaxin works against mutant viruses: Govt. Livemint. Available from: <https://www.livemint.com/news/india/24-per-10-000-people-infected-after-getting-vaccinated-govt-11619022062884.html>. Last accessed on: 6th June 2021.
10. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health.* 2020;5(9):e475-e483. doi: 10.1016/S2468-2667(20)30164-X.

11. Mutambudzi M, Niedzwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. *Occupational and Environmental Medicine* 2021;78:307-314.
12. Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. *Diabetes Metab Syndr*. 2021;15(3):1007–8.
13. Parai D, Choudhary HR, Dash GC, Sahoo SK, Pattnaik M, Rout UK, et al. Effect of a single-dose of BBV-152 and AZD1222 on Spike antibody titre among healthcare workers previously infected with SARS-CoV-2, 21 May 2021, PREPRINT (Version 1) available at Research Square. doi: 10.21203/rs.3.rs-542984/v1.
14. Rana K, Mohindra R, Pinnaka L. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med*. 2021. doi: 10.1056/NEJMc2107808.
15. Hacısuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med*. 2021 21:NEJMoa2105000. doi 10.1056/NEJMoa2105000.
16. Delhi reports more Covid case and deaths in April-May than since the beginning of the pandemic. News 18. Available from: <https://www.news18.com/news/india/delhi-reports-more-covid-cases-deaths-in-april-may-than-since-the-beginning-of-pandemic-3751346.html>. Last accessed on: 6th June, 2021.
17. Singh UB, Rophina M, Chaudhry DR, Senthivel V, Bala K, Bhojar RC, et al. Genomic analysis of symptomatic SARS-CoV-2 vaccine breakthrough infections from a tertiary care centre in India [Internet]. OSF Preprints; 2021 [cited 2021 Jun 6]. Available from: <https://osf.io/fgd4x/> Last accessed on 6th June, 2021.
18. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021 May 24;2021.05.22.21257658.
19. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet*. doi: [https://doi.org/10.1016/S0140-6736\(21\)01290-3](https://doi.org/10.1016/S0140-6736(21)01290-3)